CN103655910B - Application of compound thrombosis capsule inn aspect of liver protection - Google Patents
Application of compound thrombosis capsule inn aspect of liver protection Download PDFInfo
- Publication number
- CN103655910B CN103655910B CN201310715689.1A CN201310715689A CN103655910B CN 103655910 B CN103655910 B CN 103655910B CN 201310715689 A CN201310715689 A CN 201310715689A CN 103655910 B CN103655910 B CN 103655910B
- Authority
- CN
- China
- Prior art keywords
- liver
- fufang xueshuantong
- xueshuantong jiaonang
- group
- thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention is applicable to the field of Chinese patent medicines. A lipopolysaccharide-induced rat diffuse intravascular coagulation model is adopted for experimenting, and the experiment result shows that a compound thrombosis capsule can significantly inhibit the rise of liver-function biochemical indexes of aspartate aminotransferase and alanine aminotransferase, reduces the level of lipopolysaccharide-induced liver inflammation, and reduces congestion and hemorrhage phenomena in liver veins, namely finding out the new application of the compound thrombosis capsule playing a role of protecting the liver.
Description
Technical field
The invention belongs to technical field of Chinese patent medicine, particularly relate to the purposes of FUFANG XUESHUANTONG JIAONANG in the liver protecting.
Background technology
Cardiovascular and cerebrovascular disease has become one of the highest disease of global mortality rate, and the sickness rate of China's cardiovascular and cerebrovascular disease is also constantly soaring.Due to the maincenter that liver is sugar, fat, the large substance metabolism of protein three, lipid metabolism can cause hyperlipemia extremely, and the gallbladder in blood is admittedly liquor-saturated to be increased with triglyceride, easy atherogenicity.Therefore, whether normal the and cardiovascular disease of liver function be in close relations.Further, the main place that in liver cell or human body, multiple thrombin generates, the balance of human body intravascular coagulation and fibrinolytic also needs the normal performance of liver function.In addition, due to the existence of multiple risk factors in cardiovascular and cerebrovascular disease, often adopt the medication combined of the different mechanism of action such as blood fat reducing, blood pressure lowering in current treatment and long-term taking, and the hepar damnification that Long-term taking medicine causes also becomes the problem that can not be ignored in cardiovascular treatment.Therefore, the liver protecting research in cardiovascular and cerebrovascular diseases seems very important, and namely liver function protecting protects the Source of life of people.
FUFANG XUESHUANTONG JIAONANG is the oral Chinese medicine that first, the China jointly developed by Zhongshan University's Eye Center and Guangdong Zhongsheng Pharmaceutical Co., Ltd is used for the treatment of optical fundus blood vessel disease and cardiovascular and cerebrovascular disease, the compound Chinese patent medicine preparation be made up of Radix Notoginseng, Radix Salviae Miltiorrhizae, the Radix Astragali, Radix Scrophulariae four Chinese medicine, there is blood circulation promoting and blood stasis dispelling, effect of supplementing QI and nourishing YIN, principal indication is that blood stasis is held concurrently the retinal vein occlusion of syndrome of deficiency of both qi and yin and stability angina of effort, relates to the treatment in the fields such as fundus oculi disease, cardiovascular and cerebrovascular vessel, nephropathy, nervous system disease simultaneously.FUFANG XUESHUANTONG JIAONANG is as national secondary Chinese medicine protection kind, and national emphasis new product, after listing in 1996, clinical application effect is remarkable, defines public's praise, bring huge Social and economic benef@in doctor and patient.
Summary of the invention
The object of the invention is to: the purposes providing FUFANG XUESHUANTONG JIAONANG in the liver protecting, be intended to solve the liver protecting problem in cardiovascular and cerebrovascular diseases.
The object of the present invention is achieved like this:
The purposes of FUFANG XUESHUANTONG JIAONANG in the liver protecting,
Outstanding advantages of the present invention is: the present invention tests by adopting lipopolysaccharide-induced rat disseminated inravascular coagulation model; find that FUFANG XUESHUANTONG JIAONANG significantly can suppress the rising of liver function biochemical indicator aspartate aminotransferase, alanine aminotransferase; reduce lipopolysaccharide-induced inflammation level; reduce the congestion in hepatic vein and bleeding, namely find that FUFANG XUESHUANTONG JIAONANG has this novelty teabag of protective effect to liver.
Accompanying drawing explanation
Fig. 1 is that the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention is to the experimental result block diagram of liver function index ALT in serum;
Fig. 2 is that the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention is to the experimental result block diagram of liver function index AST in serum;
Fig. 3 is that the FUFANG XUESHUANTONG JIAONANG that provides of the embodiment of the present invention is to the experimental result picture of liver organization pathology.
Detailed description of the invention
In order to make object of the present invention, technical scheme and advantage clearly understand, below in conjunction with drawings and Examples, the present invention is further elaborated.Should be appreciated that specific embodiment described herein only in order to explain the present invention, be not intended to limit the present invention.
The present invention tests by adopting lipopolysaccharide-induced rat disseminated inravascular coagulation model; find that FUFANG XUESHUANTONG JIAONANG significantly can suppress the rising of liver function biochemical indicator aspartate aminotransferase, alanine aminotransferase; reduce lipopolysaccharide-induced inflammation level; reduce the congestion in hepatic vein and bleeding, namely find that FUFANG XUESHUANTONG JIAONANG has this novelty teabag of protective effect to liver.
Below in conjunction with specific experiment, the novelty teabag of FUFANG XUESHUANTONG JIAONANG in the liver protecting is described further.
1. laboratory animal:
SD rat, SPF level, male, body weight 150 ~ 200 g, is provided by Guangdong Medical Lab Animal Center, the animal quality certification number: SCXK(Guangdong) 2008-0002.
2. medicine grouping and process:
Normal group: normal saline.
Model control group: adopt tail vein injection lipopolysaccharide to cause rat disseminated inravascular coagulation model, give equal-volume normal saline.
FUFANG XUESHUANTONG JIAONANG low dose group: get FUFANG XUESHUANTONG JIAONANG before experiment, adds normal saline and becomes concentration to be 38 mg/ml suspensions.
Dosage group in FUFANG XUESHUANTONG JIAONANG: get FUFANG XUESHUANTONG JIAONANG before experiment and add normal saline and become concentration to be 76 mg/ml suspensions.
FUFANG XUESHUANTONG JIAONANG high dose group: get FUFANG XUESHUANTONG JIAONANG before experiment and add normal saline and become concentration to be 152 mg/ml suspensions.
3. experimental technique:
Get SD rat and be divided into 5 groups at random, be i.e. dosage group, FUFANG XUESHUANTONG JIAONANG high dose group in Normal group, model control group, positive drug control group, FUFANG XUESHUANTONG JIAONANG low dose group, FUFANG XUESHUANTONG JIAONANG, often organize 8 rats.After laboratory animal adapts to one week in feeding environment, once, administration volume is 10 mL/kg to FUFANG XUESHUANTONG JIAONANG group gastric infusion every day, successive administration 7 days.Normal group, model control group and positive drug control group gavage give same volume normal saline.In 8th day early morning, after FUFANG XUESHUANTONG JIAONANG three dosage group gastric infusion 1h, the LPS of tail vein injection 4 mg/kg manufactures rat DIC model.The normal saline of Normal group tail vein injection same volume, the LPS of positive controls tail vein injection 4 mg/kg after the heparin 1h of tail vein injection 500 IU/kg.
10% chloral hydrate (0.35 mL/100 g) anesthesia is injected for each group at lps injection 4 h pneumoretroperitoneum, postcava is taken a blood sample, after centrifugalize serum, application EOS-880 semi-automatic biochemical analyzer measures the content of aspartate aminotransferase (AST) in each group of serum, alanine aminotransferase (ALT).Test kit builds up Bioengineering Research Institute by Nanjing and provides, and the method provided by test kit measures.
Rat liver tissue is got immediately after blood-letting, after fixing 24 hours with 10% formaldehyde, through the dehydration of water displacement wash, gradient concentration 70%, 80%, 90%, 95% and anhydrous alcohol, transparent, the paraffin embedding of dimethylbenzene, be cut into 4um with cycle type microtome (LEI is with RMZ135 Germany) and cut into slices, finally carry out haematoxylin & eosin (Hematoxylin mono-Eosin, HE) dye, observe the pathologic structure of liver organization under an optical microscope.
4. experimental result:
(1) FUFANG XUESHUANTONG JIAONANG is on the impact of liver function index ALT, AST in serum
Often adopt ALT and AST as the index of liver function biochemical analysis clinically.ALT and alanine aminotransferase, AST and aspartate transaminase, the two is mainly distributed in hepatocyte.After hepatocellular degeneration necrosis, transaminase can be disengaged and be entered blood, and serum AST, ALT are raised.
From table 1, Fig. 1 and Fig. 2, compare with Normal group, model group rats serum alt and AST significantly improve (P<0.01), illustrate that lipopolysaccharide result in hepatocellular damage.All remarkable than the model group reduction of level of ALT and AST in FUFANG XUESHUANTONG JIAONANG basic, normal, high dosage group rat blood serum, difference all has statistical significance (P<0.01 or 0.05), and in dose-effect relationship.The hepatocyte injury degree that FUFANG XUESHUANTONG JIAONANG can suppress lipopolysaccharide-induced is described.Because liver synthesizes multiple thrombin, the exception of its function directly will affect the balance of hemostatic system, and FUFANG XUESHUANTONG JIAONANG, to the protective effect of liver, can explain its effect regulated and controled hemostatic system entirety.
Table 1 FUFANG XUESHUANTONG JIAONANG is on the impact () of liver function index ALT, AST in serum
The experimental group that in Fig. 1 and 2, each numeral is corresponding is: 1-Normal group; 2-model control group; 3-positive drug control group (heparin, 500 IU/kg); 4-FUFANG XUESHUANTONG JIAONANG low dose group (380 mg/kg); Dosage group (760 mg/kg) in 5-FUFANG XUESHUANTONG JIAONANG; 6-FUFANG XUESHUANTONG JIAONANG high dose group (1520 mg/kg).
(2) FUFANG XUESHUANTONG JIAONANG is on the impact of liver organization pathology
Experimental result as shown in Figure 3, wherein a: Normal group; B: model control group; C: positive drug control group (heparin, 500 IU/kg); D: FUFANG XUESHUANTONG JIAONANG low dose group (380 mg/kg); E: dosage group (760 mg/kg) in FUFANG XUESHUANTONG JIAONANG; F: FUFANG XUESHUANTONG JIAONANG high dose group (1520 mg/kg).
As seen from Figure 3, blank group rat hepatocytes, centered by central vein, radially arranges to surrounding, the hepatocyte cord structures of formation rule.Model group rats is after tail vein injection LPS 4h, and central vein has obvious congestion, and has a large amount of inflammatory cell to exist; The obvious dilatation and congestion in space between hepatic cords, with inflammatory cell infiltration; There is edema in hepatocyte, and has partial necrosis phenomenon.Positive drug heparin matched group significantly can improve the hepatic pathology of DIC rat, hepatic cords queueing discipline, though there is a small amount of inflammatory cell infiltration, without obvious congestion and bleeding.FUFANG XUESHUANTONG JIAONANG three dosage groups are compared with model group, and all improve significantly to the hepatic pathology of DIC rat, in central vein, congestion significantly reduces, and best results under high dose.Without obvious congestion and bleeding in FUFANG XUESHUANTONG JIAONANG high dose group central vein, and hepatocyte structural arrangement is neat, and inflammatory cell infiltration reduces, and effect and positive drug heparin quite, are better than in FUFANG XUESHUANTONG JIAONANG, low dose group.
According to the result of above-mentioned pathological section, can find out the improvement of liver function biochemical indicator in conjunction with above-mentioned FUFANG XUESHUANTONG JIAONANG, the liver of FUFANG XUESHUANTONG JIAONANG to DIC rat has good protective effect.Because liver function plays important regulating action in blood coagulation and anticoagulant balance, FUFANG XUESHUANTONG JIAONANG also explains FUFANG XUESHUANTONG JIAONANG from animal economy level to the protective effect of liver and plays antithrombotic mechanism.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, all any amendments done within the spirit and principles in the present invention, equivalent replacement and improvement etc., all should be included within protection scope of the present invention.
Claims (1)
1. FUFANG XUESHUANTONG JIAONANG is as the application of sole active agent in the horizontal medicine of inflammation that preparation reduction is lipopolysaccharide-induced.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715689.1A CN103655910B (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule inn aspect of liver protection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310715689.1A CN103655910B (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule inn aspect of liver protection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103655910A CN103655910A (en) | 2014-03-26 |
| CN103655910B true CN103655910B (en) | 2015-07-15 |
Family
ID=50295469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310715689.1A Active CN103655910B (en) | 2013-12-23 | 2013-12-23 | Application of compound thrombosis capsule inn aspect of liver protection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103655910B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523974A (en) * | 2014-12-31 | 2015-04-22 | 广东广发制药有限公司 | Traditional Chinese medicine preparation for preventing and treating hepatic fibrosis, soft capsule for preventing and treating hepatic fibrosis and preparing process of traditional Chinese medicine preparation and soft capsule |
| CN109771512A (en) * | 2019-01-24 | 2019-05-21 | 中山大学 | Compound Xueshuantong preparation purposes in preparing anti-inflammatory drugs |
| AU2021264907A1 (en) * | 2020-04-29 | 2022-09-15 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and application of preparation of traditional chinese medicine composition in preparing medicine for preventing and/or treating coronavirus disease 2019 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1425412A (en) * | 2002-12-17 | 2003-06-25 | 广东众生药业股份有限公司 | Compound oral thrombolytic preparation and its preparing method |
| WO2004050026A2 (en) * | 2002-12-02 | 2004-06-17 | Jiafang Chen | Compositions and methods for treating prostate cancer |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5204822B2 (en) * | 2010-09-06 | 2013-06-05 | 花王株式会社 | Method for determining constitution and constitution recommendation product recommendation system |
-
2013
- 2013-12-23 CN CN201310715689.1A patent/CN103655910B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050026A2 (en) * | 2002-12-02 | 2004-06-17 | Jiafang Chen | Compositions and methods for treating prostate cancer |
| CN1425412A (en) * | 2002-12-17 | 2003-06-25 | 广东众生药业股份有限公司 | Compound oral thrombolytic preparation and its preparing method |
Non-Patent Citations (3)
| Title |
|---|
| 复方血栓通对青年腹型肥胖患者血液流变学的作用;刘志新等;《河北中医》;20091031;第15卷(第10期);第1135-1137页，第1135页右栏第1段、第1136页表2 * |
| 复方血栓通胶囊对早期糖尿病肾病患者血清炎性指标的影响;张祯;《中国医药指南》;20131210;第11卷(第34期);第13-14页，第13页第3节第1段，第14页表2、左栏第2段 * |
| 复方血栓通胶囊对糖尿病肾病的疗效观察;刘杰;《中国优秀硕士学位论文全文数据库 医药卫生科技辑》;20111015(第10期);摘要第1页、正文第3、14、20页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103655910A (en) | 2014-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Akchurin et al. | Update on inflammation in chronic kidney disease | |
| US20210346281A1 (en) | Multi-component injection | |
| Wang et al. | The effects of Buyang Huanwu Decoction on hemorheological disorders and energy metabolism in rats with coronary heart disease | |
| Liu et al. | Neferine inhibits proliferation and collagen synthesis induced by high glucose in cardiac fibroblasts and reduces cardiac fibrosis in diabetic mice | |
| Bai et al. | Outcomes of autologous bone marrow mononuclear cell transplantation in decompensated liver cirrhosis | |
| CN103655910B (en) | Application of compound thrombosis capsule inn aspect of liver protection | |
| Li et al. | Effects of Shenfu injection in the treatment of septic shock patients: a multicenter, controlled, randomized, open-label trial | |
| Wang et al. | Effect of ethanol extract of Rhodiola rosea on the early nephropathy in type 2 diabetic rats | |
| Liu et al. | Superior effect of hypertonic saline over mannitol to attenuate cerebral edema in a rabbit bacterial meningitis model | |
| Xiping et al. | Effects of salvia miltiorrhizae on ICAM-1, TLR4, NF-κB and bax proteins expression in multiple organs of rats with severe acute pancreatitis or obstructive jaundice | |
| Liu et al. | Effects of different concentrations of mesenchymal stem cells treatment on LPS-induced acute respiratory distress syndrome rat model | |
| CN103816532A (en) | Application of recombinant ganoderma lucidum immunoregulatory protein (rLZ-8) in preparation of medicines for treating chronic cardiac failure | |
| Ding et al. | Qingchangligan formula alleviates acute liver injury by attenuating extracellular histone-associated inflammation | |
| CN102764262B (en) | Application of oleanolic acid and retinoic acid pharmaceutical composition in medicament for treating insulin resistance and diabetes | |
| CN104784192B (en) | The application of freshwater mussel meat oligosaccharides in hypoglycemic drug is prepared and preparation method thereof | |
| Magalhães et al. | Chronic kidney disease and its treatment in the elderly: an integrative review | |
| CN101461802A (en) | Application of epi-gallocatechin-3-gallate in preparing medicament for preventing and treating high-fat fatty liver | |
| Hijikata et al. | Treatment for intractable anemia with the traditional Chinese medicines Hominis Placenta and Cervi Cornus Colla (deer antler glue) | |
| CN105213405A (en) | Dihydrotanshinone I is preparing the application in anti-hepatic fibrosis medicines | |
| CN103655909A (en) | Application of compound thrombosis capsule in aspect of kidney protection | |
| Meng et al. | Immunomodulatory effects of Blaps rynchopetera extract | |
| Zeng et al. | Study on the protective mechanism of dexmedetomidine on the liver of perioperative diabetic patients: A randomized controlled trial | |
| CN104546697A (en) | Dexibuprofen injection drug composition and preparation method thereof | |
| Sun et al. | Effect of alloxan time administerDrug on establishing diabetic rabbit model | |
| CN103330836A (en) | Traditional Chinese medicine composition for treating diabetes mellitus, and application of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |